• The technology described in this briefing is MMprofiler. It is used for assessing the risk of disease progression in multiple myeloma.

  • The innovative aspects are the unique SKY92 gene expression signature. This has been developed into a validated clinical test which the company claims could improve risk classification and result in more tailored drug treatment regimens.

  • The intended place in therapy would be alongside standard care markers for newly diagnosed, relapsed or refractory multiple myeloma.

  • The main points from the evidence summarised in this briefing are from 6 studies (3 secondary analyses with 2 based on randomised controlled trials, 1 analytical validation, 1 prospective case series, and 1 prospective single-arm trial) including 5,532¬†people. They show that MMprofiler (SKY92) can be effective as a prognostic marker for multiple myeloma.

  • Key uncertainties around the evidence or technology are that several studies were secondary analyses validating MMprofiler as a prognostic marker for multiple myeloma. Further evidence is needed evaluating the use of MMprofiler in treatment decisions and its effect on clinical outcomes compared with standard care markers. Further prospective comparative research is also needed on risk-stratified treatment for multiple myeloma.

  • The cost of MMprofiler is ¬£2,800 per person (excluding VAT) in addition to standard care.